Bausch + Lomb has enrolled the first patient in a clinical trial of the enVista MX60EF trifocal IOL, according to a press release.
The multicenter, randomized study is evaluating the efficacy and safety of the lens. It will include more than 500 patients undergoing bilateral cataract surgery who are randomly assigned to receive the trifocal IOL or the enVista MX60E monofocal IOL, the release said.
The study of the single-piece, ultraviolet-absorbing posterior chamber IOL is intended to support a premarket approval application filing with the FDA. Based on postoperative observation, efficacy
Uncategorized